Castle Biosciences, Inc.
Castle Biosciences, Inc., a leading biotechnology company headquartered in the United States, specialises in innovative diagnostic solutions for skin cancer and other complex diseases. Founded in 2007, the company has made significant strides in the field of personalised medicine, particularly with its flagship products, the DecisionDx® tests, which provide critical insights for melanoma and non-melanoma skin cancers. With a strong presence across the US and expanding operations internationally, Castle Biosciences is recognised for its commitment to improving patient outcomes through advanced genomic testing. The company has achieved notable milestones, including the successful launch of its proprietary tests that help clinicians make informed treatment decisions. As a pioneer in the dermatological diagnostics industry, Castle Biosciences continues to set the standard for precision medicine, solidifying its position as a trusted partner in oncology care.
DitchCarbon Score
How does Castle Biosciences, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Castle Biosciences, Inc.'s score of 25 is higher than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Castle Biosciences, Inc.'s reported carbon emissions
In 2022, Castle Biosciences, Inc. reported total carbon emissions of approximately 755,080 kg CO2e, which includes 24,130 kg CO2e from Scope 1 emissions and 730,950 kg CO2e from Scope 2 emissions (market-based). The previous year, 2021, saw similar figures with total emissions also around 755,080 kg CO2e, indicating a consistent emission profile. Castle Biosciences has not disclosed any specific reduction targets or initiatives aimed at decreasing their carbon footprint. The company has reported emissions data for Scope 1 and Scope 2 but has not provided information regarding Scope 3 emissions. As a company headquartered in the US, Castle Biosciences is part of a growing trend in the biotechnology sector, where firms are increasingly recognising the importance of climate commitments and transparency in emissions reporting. However, without defined reduction targets, their long-term climate strategy remains unclear.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | |
|---|---|---|
| Scope 1 | 24,130 | 00,000 |
| Scope 2 | 730,950 | 000,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Castle Biosciences, Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
